Reducing Clinical-Phase Manufacturing Costs: Collaborating for Savings without Compromising Quality or Performance Publication
In downstream purification of monoclonal antibodies (MAbs), the single greatest contributor to manufacturing costs is the expensive capture step typically based on protein A affinity chromatography. Almost since its introduction to bioprocessing, efforts have been made to reduce the cost of this step.